The Emirates Drug Establishment has approved Miebo, a prescription eye drop developed by Bausch + Lomb, marking a significant step forward in the UAE's access to advanced ophthalmic care.
Developed with the active substance perfluorohexyloctane, Miebo is the first prescription eye drop clinically designed to directly target tear evaporation, a primary driver of dry eye disease. The treatment works by improving tear film stability and relieving symptoms associated with the condition.
The UAE joins an exclusive group of countries to have cleared the treatment, becoming only the third globally to approve Miebo, reflecting the country's continued push to align its pharmaceutical ecosystem with international standards.
Regulatory approval was granted on the strength of two clinical trials, GOBI and MOJAVE, which together enrolled more than 1,200 patients. Both studies recorded statistically significant improvements in disease signs and symptoms over the treatment period.
Dry eye disease affects millions of people worldwide and can meaningfully impact visual comfort and overall quality of life, making targeted treatment options a growing priority in eye care.
News Source: Emirates News Agency
